Drug Trial Radar · NCT01922050
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
320
Actual
Start
Oct 2013
Primary completion
Nov 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle formulations
Conditions
- Actinic Keratosis
Interventions
LEO 43204 Formulation 1Drug
LEO 43204 Formulation 2Drug
LEO 43204 Formulation 1 Dose XDrug
LEO 43204 Formulation 1 Dose YDrug
LEO 43204 Formulation 2 Dose XXDrug
LEO 43204 Formulation 2 Dose YYDrug
Placebo Formulation 1Drug
Placebo Formulation 2Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs)Time frame: From Day 1 up to and including Day 8
- Part 2: Percent Reduction From Baseline in Actinic Keratosis (AK) Counts (Multiple Imputation)Time frame: At Week 8
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Omni Dermatology
Phoenix, Arizona
Torrance Clinical Research Institute Inc.
Lomita, California
Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.
San Diego, California
Leavitt Medical Associates of Florida
Ormond Beach, Florida
Clinical Research Center, Morsani Center for Advanced Healthcare
Tampa, Florida
Research Institute of Deaconess Clinic
Evansville, Indiana
Hudson Dermatology, LLC
Evansville, Indiana
DermAssociates, PC
Rockville, Maryland
Great Lakes Research Group, Inc.
Bay City, Michigan
Henry Ford Medical Center, Dept. of Dermatology
West Bloomfield, Michigan
The Dermatology Group, P.C.
Verona, New Jersey
Mount Sinai School of Medicine
New York, New York
Clinical Trials of Texas, Inc.
San Antonio, Texas
Stratica Medical Inc.
Edmonton, Alberta, Canada
Guildford Dermatology Specialists
Surrey, British Columbia, Canada
Durondel C.P. Inc./Dermatology Clinic
Moncton, New Brunswick, Canada
Ultranova Skincare
Barrie, Ontario, Canada
Co-Medica Research Network Inc.
Courtice, Ontario, Canada
Dermatrials Research Incorporated
Hamilton, Ontario, Canada
The Guenther Dermatology Research Centre
London, Ontario, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
K. Papp Clinical Research
Waterloo, Ontario, Canada
XLR8 Medical Research
Windsor, Ontario, Canada
Centre de Recherche Dermatologique du Quebec Metropolitain
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.